For now FDA will continue to allow pharmacies to provide compounded hydroxyprogesterone caproate
April 1st 2011FDA "...does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products," according to a statement.
Read More
FDA warns of risks associated with the use of antipsychotic medications in pregnancy
April 1st 2011FDA recently announced that the 'Pregnancy' sections of labeling for all antipsychotic medications will now have to include wording about the potential risk for extrapyramidal side effects and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy.
Read More
Health reform controversies pose new challenges for drug plans and healthcare providers
April 1st 2011There's growing uncertainty about how the Obama healthcare reform program will be implemented, and how proposed changes will affect biomedical product development and coverage of prescription drugs.
Read More
Ambulatory blood pressure lowering efficacy of hydrochlorothiazide inferior to other drug classes
April 1st 2011Investigators question whether the thiazide diuretic, hydrochlorothiazide, should be used as commonly as it is for treating hypertension, according to a report published in a recent edition of the Journal of the American College of Cardiology.
Read More
Belimumab: A B-lymphocyte stimulator inhibitor for-systemic lupus erythematosus
April 1st 2011Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator that has been FDA approved for the treatment of systemic lupus erythematosus. It is the first new drug for the treatment of SLE approved in more than 50 years.
Read More
Patients using brand-name or generic antidepressant medications to treat major depressive disorder have similar drug discontinuation rates and accrue comparable healthcare costs during the first 6 months of treatment, according to a study published in March 2011 in the Journal of Managed Care Pharmacy.
Read More
Cost of heart failure drugs impacts medication adherence
April 1st 2011In a new study published ahead of print on the Mayo Clinic Proceedings website, researchers demonstrated that the cost of medications was a factor influencing the proportion of patients with heart failure who had poor medication adherence to beta-blockers, angiotensin converting-enzyme inhibitors or receptor blockers, and statins.
Read More
Intensive glycemic management leads to higher mortality in type 2 diabetes mellitus patients
April 1st 2011The management of type 2 diabetes mellitus needs to change in response to the evolving evidence base now available. Research from the ADVANCE and the ACCORD trials was presented during the American Diabetes Association 58th annual advanced postgraduate course in New York City.
Read More
Too early to predict impact of biosimilars on utilization of hematopoietic growth factors
April 1st 2011Overall, it would not appear that the new erythropoiesis-stimulating agents for treatment of cytopenia will add substantially to pharmacy budgets. As they are approved by FDA, each medication will need to be reviewed to understand its complete clinical advantage, and the safety profile will need to be completely understood.
Read More
New guidelines for atrial fibrillation management incorporate dabigatran
April 1st 2011An update on the management of atrial fibrillation issued by a task force consisting of the American College of Cardiology Foundation, the American Heart Association, and the Heart Rhythm Society has incorporated dabigatran into its recommendations.
Read More
Metastatic breast cancer: A review of current and novel pharmacotherapy
April 1st 2011Despite advancements, treatment of metastatic breast cancer hinges on multifarious factors and numerous unanswered questions about therapy linger. Agents that are highly active in heavily pretreated patients are needed to optimize outcomes in patients with metastatic disease. This article reviews current and novel treatment options for metastatic breast cancer.
Read More